Altay Therapeutics Closes $37M Series A for Oral FSHD Drug

Sound Bioventures invests around the point when a medicine is ready to move into clinical development. Its decision to co-lead Altay Therapeutics' latest financing puts that investment boundary inside a very specific obligation: finding out whether an oral candidate can help preserve muscle in people living with facioscapulohumeral muscular dystrophy, or FSHD.

The San Carlos, California biotechnology company completed a $37M Series A on October 14, 2026. Sound Bioventures and HealthCap co-led the round, with Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund participating as new investors. Altay plans to use the proceeds for Phase 1 and Phase 2 proof-of-concept trials of DX5057, its investigational oral DUX4 inhibitor.

CEO James Breitmeyer expects a Phase 1 safety study to begin in Q1 2027. That gives the financing a clear development purpose, while leaving the patient benefit to be established through human studies. For a disease community already involved in financing the science, the new syndicate brings more institutions into the work of carrying a candidate toward clinical evidence.

A clinical financing with a longer funding history

Sound Bioventures describes its mandate as backing companies approaching or already in clinical development, across Europe and the United States. Altay fits that transition unusually closely. The money is directed toward the safety and proof-of-concept stages at which the company's molecular idea begins to encounter the realities of a clinical program.

HealthCap lists Altay in its portfolio and describes a business built around selective inhibitors of transcription factors. Those proteins influence the activity of other genes, making them consequential targets and demanding design problems. The investment connects a broader discovery approach with a lead program that has a defined disease and an intended clinical path.

Earlier support remains part of the capital story. Altay reports that SOLVE FSHD has invested nearly $7M in seed financing since 2022 and provided strategic and board-level leadership. Founder and CSO Ali Ozes also credits Friends of FSH Research and FSHD Global Research Foundation with early support. That history brings a different constituency into the financing: organizations whose purpose is advancing treatments for the people living with the disease.

The announced $37M is the Series A close. A complete lifetime funding total and a valuation were not disclosed, so the earlier seed support stays separate in the accounting. Describing the financing precisely preserves the work of those earlier supporters without turning incomplete historical figures into a tidy cumulative number.

An oral candidate aimed at a gene-regulating protein

Altay's platform searches for binding opportunities in transcription factors that have been difficult to address with conventional small-molecule approaches. The company describes allosteric sites that appear as a protein's structure changes, rather than relying only on a readily visible fixed pocket. That scientific choice is central to the company the founders have built.

DX5057 applies the approach to DUX4, whose abnormal activity in skeletal muscle is involved in FSHD. Altay's intended oral route is commercially and practically relevant because administration becomes part of a long-term treatment relationship. The convenience argument, however, depends on a candidate achieving suitable exposure, tolerability and meaningful benefit in clinical development.

Altay has described activity in nonclinical models. Those findings support the decision to develop DX5057, while the planned human program will have its own questions to answer. The announcement's Phase 1 safety timing provides a near-term milestone; the later proof-of-concept work is where measurements of disease biology and muscle function enter the larger development story.

FSHD developers are also building ways to measure change

Altay enters a field with other investigational approaches already advancing. Novartis reported in June that the biomarker cohort in the FORTITUDE Phase I/II study of delpacibart braxlosiran, or del-brax, met primary and key secondary endpoints. The company also said its Phase III study was enrolling. Del-brax uses an antibody-oligonucleotide conjugate, giving investors another development approach to consider alongside Altay's small molecule.

The different modalities make clinical evidence particularly important to interpretation. A route of administration describes how a patient would receive a medicine; it supplies no reliable ranking of outcomes across separate trials. Altay's financing should be read as backing its approach and development plan, with comparative conclusions reserved for evidence capable of supporting them.

The FSHD Industry Collaborative supplies another part of the market context. Altay joined a pre-competitive effort led by the FSHD Society, SOLVE FSHD and the FSHD Clinical Trial Research Network. Its work includes blood biomarkers, assay validation, endpoint analysis and MRI analytics, all aimed at improving the tools developers use to evaluate potential treatments.

For operators, that shared infrastructure is an important relationship to recognize. Multiple companies can pursue distinct medicines while contributing to a better understanding of progression and treatment effects. A clinical program needs both a candidate worth evaluating and measurements capable of making its results useful.

A wider board carries the program toward its safety study

Altay was founded in 2019, and its current team identifies Ali Ozes and Osman N. Ozes as founders. James Breitmeyer serves as CEO; Alejandro Dorenbaum is listed as CMO. The combination ties the founding scientific effort to executives responsible for moving a drug-development organization into its next stage.

The financing brings 4 incoming directors: Ester Sklarsky of Sound Bioventures, Carl Kilander of HealthCap, Aidan King of Fountain Healthcare Partners and Chelsea Johnson of Biogen New Ventures. They join Executive Chairman Mike Grey, Eric Bjerkholt and James Breitmeyer. The investor table is becoming part of the company's governance at the moment its lead candidate approaches human study.

For the institutions that supported Altay early, the relationship now extends into a larger financing and a more specific clinical schedule. For the new investors, participation carries responsibility for the work behind that schedule. DX5057's planned first safety study will begin the next exchange between the founders' molecular approach, the people running the trials and the disease community that helped bring the program this far.